

REPORT DOCUMENTATION PAGE				Form Approved OMB NO. 0704-0188	
<p>The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA, 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.</p> <p>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</p>					
1. REPORT DATE (DD-MM-YYYY) 12-06-2014		2. REPORT TYPE Final Report		3. DATES COVERED (From - To) 25-Mar-2013 - 25-May-2014	
4. TITLE AND SUBTITLE Enhancing the Pharmacokinetic Profile of Protein-Based Drugs				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W911NF-13-C-0033	
				5c. PROGRAM ELEMENT NUMBER 606055	
6. AUTHORS Tarik Soliman, Laura Hales, Dan Hall				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAMES AND ADDRESSES Extend Biosciences Inc. 48 Russell St. #3  Cambridge, MA 02140 -1310				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS (ES) U.S. Army Research Office P.O. Box 12211 Research Triangle Park, NC 27709-2211				10. SPONSOR/MONITOR'S ACRONYM(S) ARO	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S) 63065-CH-CBD.1	
12. DISTRIBUTION AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision, unless so designated by other documentation.					
14. ABSTRACT Many protein-based drugs have limited efficacy due to a short half-life or require intravenous delivery because of low bioavailability when given subcutaneously. Extend Biosciences is developing proprietary carrier molecules that will allow proteins to access a transport pathway for efficient delivery to the vascular space and then maintain a sustained presence in circulation. This would be of particular importance in the development of longer-lasting versions of bioscavenger proteins that could then be delivered subcutaneously and become bioavailable within minutes of administration. In this project, one of Extend Biosciences' carrier molecules will be conjugated to two					
15. SUBJECT TERMS BCHE, PON1					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON Laura Hales
a. REPORT UU	b. ABSTRACT UU	c. THIS PAGE UU			19b. TELEPHONE NUMBER 732-599-8581

## Report Title

Enhancing the Pharmacokinetic Profile of Protein-Based Drugs

### ABSTRACT

Many protein-based drugs have limited efficacy due to a short half-life or require intravenous delivery because of low bioavailability when given subcutaneously. Extend Biosciences is developing proprietary carrier molecules that will allow proteins to access a transport pathway for efficient delivery to the vascular space and then maintain a sustained presence in circulation. This would be of particular importance in the development of longer-lasting versions of bioscavenger proteins that could then be delivered subcutaneously and become bioavailable within minutes of administration. In this project, one of Extend Biosciences' carrier molecules will be conjugated to two bioscavenger proteins of interest to the military as further proof-of-concept for the technology. The modified bioscavengers will be assayed in vitro to ensure that the carrier molecule does not disrupt functional activity. Following success in Phase I, the Phase II studies would test the modified bioscavengers for their improved half-life and bioavailability when delivered subcutaneously in an appropriate animal model, and test whether the modified protein induces toxicity or an immune response. This project will demonstrate the feasibility of improving the half-life and bioavailability of bioscavenger proteins that could be applied to numerous other protein-based drugs including those used in Chemical and Biological Defense treatments.

---

**Enter List of papers submitted or published that acknowledge ARO support from the start of the project to the date of this printing. List the papers, including journal references, in the following categories:**

**(a) Papers published in peer-reviewed journals (N/A for none)**

<u>Received</u>	<u>Paper</u>
-----------------	--------------

**TOTAL:**

**Number of Papers published in peer-reviewed journals:**

---

**(b) Papers published in non-peer-reviewed journals (N/A for none)**

<u>Received</u>	<u>Paper</u>
-----------------	--------------

**TOTAL:**

**Number of Papers published in non peer-reviewed journals:**

---

**(c) Presentations**

Number of Presentations: 0.00

Non Peer-Reviewed Conference Proceeding publications (other than abstracts):

Received Paper

TOTAL:

Number of Non Peer-Reviewed Conference Proceeding publications (other than abstracts):

Peer-Reviewed Conference Proceeding publications (other than abstracts):

Received Paper

TOTAL:

Number of Peer-Reviewed Conference Proceeding publications (other than abstracts):

(d) Manuscripts

Received Paper

TOTAL:

Number of Manuscripts:

Books

Received Book

TOTAL:

TOTAL:

Patents Submitted

Patents Awarded

Awards

Graduate Students

<u>NAME</u>	<u>PERCENT SUPPORTED</u>
FTE Equivalent:	
Total Number:	

Names of Post Doctorates

<u>NAME</u>	<u>PERCENT SUPPORTED</u>
FTE Equivalent:	
Total Number:	

Names of Faculty Supported

<u>NAME</u>	<u>PERCENT SUPPORTED</u>
FTE Equivalent:	
Total Number:	

Names of Under Graduate students supported

<u>NAME</u>	<u>PERCENT SUPPORTED</u>
FTE Equivalent:	
Total Number:	

### Student Metrics

This section only applies to graduating undergraduates supported by this agreement in this reporting period

The number of undergraduates funded by this agreement who graduated during this period: ..... 0.00

The number of undergraduates funded by this agreement who graduated during this period with a degree in science, mathematics, engineering, or technology fields:..... 0.00

The number of undergraduates funded by your agreement who graduated during this period and will continue to pursue a graduate or Ph.D. degree in science, mathematics, engineering, or technology fields:..... 0.00

Number of graduating undergraduates who achieved a 3.5 GPA to 4.0 (4.0 max scale):..... 0.00

Number of graduating undergraduates funded by a DoD funded Center of Excellence grant for Education, Research and Engineering:..... 0.00

The number of undergraduates funded by your agreement who graduated during this period and intend to work for the Department of Defense ..... 0.00

The number of undergraduates funded by your agreement who graduated during this period and will receive scholarships or fellowships for further studies in science, mathematics, engineering or technology fields: ..... 0.00

### Names of Personnel receiving masters degrees

NAME

**Total Number:**

### Names of personnel receiving PHDs

NAME

**Total Number:**

### Names of other research staff

NAME

PERCENT SUPPORTED

**FTE Equivalent:**

**Total Number:**

### Sub Contractors (DD882)

### Inventions (DD882)

### Scientific Progress

### Technology Transfer



700 MAIN ST.  
CAMBRIDGE, MA 02139  
(732) 599-8580  
[WWW.EXTENDBIO.COM](http://WWW.EXTENDBIO.COM)

## MONTHLY PROGRESS REPORT

Contract Number: W911NF-13-C-0033

Phase I option SBIR Proposal Number: C122-101-0073

Title: Enhancing the Pharmacokinetic Profile of Protein-Based Drugs

Performance Period: 02/25/14 – 05/24/14

Contract Amount: \$49,999

Total Paid-to-date: \$33,332.68

Amount Expended-to-date: \$30,460.41

Number of Employees Working on the Project: 3

Number of New Employees Placed on the Contract: 0

Deliverables: Data on the Carrier:Protein ratios (CONFIDENTIAL)

Work Period: 04/25/14 – 05/25/14

**Task 1. Confirm that the carrier molecule(s) are attached to purified BCHE and PON1 by mass spectrometry.**

During the previous work period, BCHE was deglycosylated and purified using ZipTips (Millipore) and submitted for MS analysis to Boston University's Core Facility. We received the results after a long delay due to equipment-related problems. No products within the correct mass range were detected.

An identically prepared sample of BCHE was deglycosylated and purified and sent to the core facility at Yale University as a backup. Again, we experienced a long delay due to instrument calibration and throughput issues. We did receive results and observed a strong signal for deglycosylated BChE with peaks at 66.1, 67.8, and 69.7 kD. This correlates well with the theoretical mass of 65 kD for the completely deglycosylated protein and indicates that glycosylation is not complete. The spectrum for native BChE did not yield any signal above background; this is expected due to the very heterogeneous nature of the glycosylation. Both of the above academic facilities used electrospray ionization (ESI) MS.

As an alternative to ESI and academic core facilities, identical samples were submitted to HT Laboratories (San Diego, CA) for MALDI-TOF MS analysis. A very broad signal for native BChE was obtained with a peak at 78 kD (range at half-peak height = 70-80

kD). A narrower, but still broad peak for deglycosylated BChE was observed at 66 kD (range 63.5-69 kD). This mass range correlates with the expected mass and the ESI MS results described above.

The next goal is to observe an increase in mass upon conjugation of the carrier molecule to BChE. To this end, BChE was reacted with 0, 3, or 10 equivalents of the NHS-activated carrier. The reactions were deglycosylated, desalted by ZipTip, and submitted for MALDI-TOF MS analysis. The 0 equivalent control reaction yielded a peak centered at 65.7 kD, while the 3 and 10 equivalent reactions were 69.4 kD, an increase of 3.7 kD corresponding to 1.5 carriers per BChE.

We have signed the amended Material Transfer Agreement (MTA) from the University of Nebraska to obtain Dr. Oksana Lockridge's CHO-K1 cell line that expresses BCHE for expression and purification for work in Phase II. We expect to obtain the cell line from Dr. Lockridge in the next reporting period.

We are actively interviewing candidates for an open position for cell culture and protein purification related to the project.

During the work period, Extend Biosciences also undertook some independent research and development (IR&D) activities. We would like to obtain additional proof-of-concept data for the use of the technology.

During this work period, no problems were encountered. No changes to the planned schedule have occurred.

#### Proposed Work for the Following Period: 05/25/14 – 06/25/14

During the next month, we will continue to work on the MS analysis and will move on to testing and characterizing different reaction conditions including higher carrier to BChE ratios. We hope to be able to receive the cell line in-house. We will hope to hire an appropriate candidate that has cell culture expertise.

Extend Biosciences will continue working on a small IR&D project. No bid and proposal work is expected during this period.